Valuation: Legend Biotech Corporation

Capitalization 5.2B 4.47B 4.18B 3.9B 7.2B 468B 7.83B 48.93B 18.89B 221B 19.5B 19.08B 807B P/E ratio 2025 *
-33.4x
P/E ratio 2026 * 52.2x
Enterprise value 5.02B 4.31B 4.04B 3.77B 6.95B 451B 7.56B 47.25B 18.24B 213B 18.83B 18.43B 780B EV / Sales 2025 *
4.84x
EV / Sales 2026 * 3.03x
Free-Float
98.8%
Yield 2025 *
-
Yield 2026 * -
More valuation ratios * Estimated data
Dynamic Chart
1 day+1.15%
1 week+1.52%
Current month+1.52%
1 month-13.10%
3 months-22.03%
6 months-19.63%
Current year-13.55%
More quotes
1 week 26.43
Extreme 26.43
28.97
1 month 25.71
Extreme 25.71
33.5
Current year 25.71
Extreme 25.71
45.3
1 year 25.71
Extreme 25.71
45.3
3 years 25.71
Extreme 25.71
77.32
5 years 23.41
Extreme 23.41
77.32
10 years 23.41
Extreme 23.41
77.32
More quotes
Manager TitleAgeSince
Chief Executive Officer 52 20/09/2020
Chief Tech/Sci/R&D Officer 47 10/04/2023
Chief Tech/Sci/R&D Officer - 30/04/2018
Director TitleAgeSince
Chairman 56 05/11/2020
Director/Board Member 52 29/12/2021
Director/Board Member 68 30/04/2020
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
+1.15%+1.52%-32.28%-47.87% 5.2B
-2.68%-1.46%+30.50%+106.92% 54.89B
-0.51%-1.81%+170.56%+974.82% 43.51B
+0.90%-0.87%+63.71%+15.59% 38.12B
+0.26%-6.69%-20.93%-40.45% 23.14B
-1.45%-0.34%+31.18%-37.38% 19.5B
-0.97%+4.69%+88.12%-38.57% 17.25B
+0.57%+0.98%+90.34%+298.39% 14.68B
-2.66%+2.35%-1.24%+692.64% 14.12B
+2.45%+0.79%+149.73% - 13.78B
Average -0.29%-0.20%+56.97%+213.79% 24.42B
Weighted average by Cap. -0.67%-1.03%+67.05%+262.39%
See all sector performances

Financials

2025 *2026 *
Net sales 1.04B 892M 835M 779M 1.44B 93.35B 1.56B 9.77B 3.77B 44.09B 3.89B 3.81B 161B 1.57B 1.35B 1.26B 1.18B 2.17B 141B 2.36B 14.76B 5.7B 66.62B 5.88B 5.76B 244B
Net income -258M -222M -208M -194M -358M -23.23B -389M -2.43B -939M -10.97B -969M -948M -40.12B 141M 122M 114M 106M 196M 12.72B 213M 1.33B 514M 6.01B 531M 519M 21.97B
Net Debt -179M -154M -144M -134M -248M -16.1B -270M -1.69B -651M -7.61B -672M -657M -27.81B -450M -387M -363M -338M -624M -40.52B -679M -4.24B -1.64B -19.14B -1.69B -1.65B -69.97B
More financial data * Estimated data
Logo Legend Biotech Corporation
Legend Biotech Corporation is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in several hematologic malignancies, including multiple myeloma (MM). In addition to cilta-cel, the Company has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It is also engaged in developing an allogeneic gamma delta CAR-T product candidate and an allogeneic CAR-NK product candidate targeting BCMA for MM.
Employees
2,900
More about the company
Date Price Change Volume
05/12/25 28.13 $ +1.15% 1,711,143
04/12/25 27.81 $ +0.22% 1,491,930
03/12/25 27.75 $ +3.97% 930,925
02/12/25 26.69 $ -0.56% 1,565,033
01/12/25 26.84 $ -3.14% 1,496,467

Delayed Quote Nasdaq, December 05, 2025 at 09:00 pm

More quotes
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
28.13USD
Average target price
74.91USD
Spread / Average Target
+166.29%
Consensus

Quarterly revenue - Rate of surprise